Literature DB >> 26148861

PD-L1 expression in small cell lung cancer.

Takefumi Komiya1, Rashna Madan2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26148861     DOI： 10.1016/j.ejca.2015.06.003

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  15 in total

Review 1.  Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.

Authors:  Marius Ilie; Véronique Hofman; Manfred Dietel; Jean-Charles Soria; Paul Hofman
Journal:  Virchows Arch       Date:  2016-02-25       Impact factor: 4.064

2.  PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.

Authors:  Hui Yu; Cory Batenchuk; Andrzej Badzio; Theresa A Boyle; Piotr Czapiewski; Daniel C Chan; Xian Lu; Dexiang Gao; Kim Ellison; Ashley A Kowalewski; Christopher J Rivard; Rafal Dziadziuszko; Caicun Zhou; Maen Hussein; Donald Richards; Sharon Wilks; Marc Monte; William Edenfield; Jerome Goldschmidt; Ray Page; Brian Ulrich; David Waterhouse; Sandra Close; Jacek Jassem; Kimary Kulig; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-09-14       Impact factor: 15.609

Review 3.  Immune checkpoint inhibitors and small cell lung cancer: what's new?

Authors:  Sabine Schmid; Martin Früh
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 4.  PD-L1 Expression in Lung Cancer.

Authors:  Hui Yu; Theresa A Boyle; Caicun Zhou; David L Rimm; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-04-23       Impact factor: 15.609

5.  Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.

Authors:  Zhifang Chen; Nannan Pang; Rong Du; Yuejie Zhu; Lingling Fan; Donghui Cai; Yan Ding; Jianbing Ding
Journal:  Mediators Inflamm       Date:  2016-09-05       Impact factor: 4.711

6.  High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells.

Authors:  Xue Chen; Qi Zhang; Youjun Luo; Caixia Gao; Xibing Zhuang; Guoxiong Xu; Tiankui Qiao
Journal:  Onco Targets Ther       Date:  2016-10-21       Impact factor: 4.147

7.  Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.

Authors:  Kentaro Inamura; Yusuke Yokouchi; Maki Kobayashi; Hironori Ninomiya; Rie Sakakibara; Makoto Nishio; Sakae Okumura; Yuichi Ishikawa
Journal:  Cancer Med       Date:  2017-09-18       Impact factor: 4.452

8.  High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.

Authors:  Yih-Leong Chang; Ching-Yao Yang; Yen-Lin Huang; Chen-Tu Wu; Pan-Chyr Yang
Journal:  Oncotarget       Date:  2017-03-14

Review 9.  [Recent Advances and Future Strategies for Small Cell Lung Cancer].

Authors:  Weipeng Shao; Xiaowei Wang; Deruo Liu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-06-20

10.  Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy.

Authors:  Yu-E Qin; Wen-Fan Tang; Yun Xu; Fu-Rong Wan; Ai-Hua Chen
Journal:  Cancer Manag Res       Date:  2020-04-05       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.